D.E. Shaw & Co
ACAD icon

D.E. Shaw & Co’s Acadia Pharmaceuticals ACAD Stock Holding History

D.E. Shaw & Co’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.2M Sell
729,836
-296,949
-29% -$7.1M 0.01% 1281
2025
Q4 		$27.4M Sell
1,026,785
-534,376
-34% -$12.8M 0.02% 1040
2025
Q3 		$33.3M Sell
1,561,161
-403,360
-21% -$9.54M 0.02% 868
2025
Q2 		$42.4M Sell
1,964,521
-384,899
-16% -$7.15M 0.03% 639
2025
Q1 		$39M Sell
2,349,420
-891,986
-28% -$16.2M 0.03% 585
2024
Q4 		$59.5M Sell
3,241,406
-263,551
-8% -$4.25M 0.04% 497
2024
Q3 		$53.9M Buy
3,504,957
+570,031
+19% +$9.51M 0.05% 475
2024
Q2 		$47.7M Buy
2,934,926
+292,906
+11% +$4.73M 0.04% 473
2024
Q1 		$48.9M Sell
2,642,020
-1,112,578
-30% -$27.6M 0.04% 488
2023
Q4 		$118M Sell
3,754,598
-1,034,400
-22% -$24.7M 0.1% 233
2023
Q3 		$99.8M Sell
4,788,998
-474,080
-9% -$12.9M 0.1% 221
2023
Q2 		$126M Buy
5,263,078
+362,496
+7% +$8.06M 0.13% 180
2023
Q1 		$92.2M Buy
4,900,582
+681,183
+16% +$13M 0.1% 240
2022
Q4 		$67.2M Sell
4,219,399
-492,781
-10% -$7.7M 0.07% 312
2022
Q3 		$77.1M Buy
4,712,180
+25,515
+0.5% +$413K 0.09% 242
2022
Q2 		$66M Buy
4,686,665
+139,702
+3% +$2.61M 0.08% 297
2022
Q1 		$110M Buy
4,546,963
+19,760
+0.4% +$478K 0.1% 207
2021
Q4 		$106M Sell
4,527,203
-1,043,329
-19% -$21M 0.09% 252
2021
Q3 		$92.5M Buy
5,570,532
+805,467
+17% +$15.5M 0.08% 280
2021
Q2 		$116M Buy
4,765,065
+2,409,857
+102% +$54.4M 0.1% 228
2021
Q1 		$60.8M Buy
2,355,208
+112,408
+5% +$4.95M 0.06% 403
2020
Q4 		$120M Sell
2,242,800
-21,713
-1% -$1.08M 0.11% 219
2020
Q3 		$93.4M Buy
2,264,513
+116,305
+5% +$5.02M 0.1% 243
2020
Q2 		$104M Buy
2,148,208
+858,079
+67% +$41.2M 0.12% 168
2020
Q1 		$54.5M Sell
1,290,129
-86,965
-6% -$3.58M 0.09% 265
2019
Q4 		$58.9M Sell
1,377,094
-895,290
-39% -$38.9M 0.07% 335
2019
Q3 		$81.8M Buy
2,272,384
+370,534
+19% +$11.2M 0.1% 241
2019
Q2 		$50.8M Buy
1,901,850
+461,869
+32% +$11.8M 0.06% 374
2019
Q1 		$38.7M Buy
1,439,981
+1,290,639
+864% +$30.1M 0.05% 452
2018
Q4 		$2.42M Buy
+149,342
New +$2.9M ﹤0.01% 1995
2018
Q3 		– Sell
-56,267
Closed -$859K – 3687
2018
Q2 		$859K Buy
+56,267
New +$1M ﹤0.01% 2793
2017
Q4 		– Sell
-18,429
Closed -$589K – 3549
2017
Q3 		$694K Buy
+18,429
New +$600K ﹤0.01% 2726
2017
Q2 		– Sell
-6,358
Closed -$189K – 3335
2017
Q1 		$219K Sell
6,358
-45,088
-88% -$1.59M ﹤0.01% 3085
2016
Q4 		$1.48M Sell
51,446
-54,437
-51% -$1.44M ﹤0.01% 2218
2016
Q3 		$3.37M Buy
105,883
+98,063
+1,254% +$3.32M 0.01% 1553
2016
Q2 		$254K Sell
7,820
-20,746
-73% -$694K ﹤0.01% 3097
2016
Q1 		$799K Sell
28,566
-36,184
-56% -$789K ﹤0.01% 2509
2015
Q4 		$2.31M Buy
64,750
+17,974
+38% +$633K ﹤0.01% 2023
2015
Q3 		$1.55M Buy
46,776
+1,445
+3% +$60.1K ﹤0.01% 2281
2015
Q2 		$1.9M Buy
45,331
+15,882
+54% +$615K ﹤0.01% 2241
2015
Q1 		$960K Sell
29,449
-144,752
-83% -$4.98M ﹤0.01% 2586
2014
Q4 		$5.53M Buy
174,201
+38,562
+28% +$1.09M 0.01% 1493
2014
Q3 		$3.36M Buy
135,639
+8,424
+7% +$197K ﹤0.01% 1828
2014
Q2 		$2.87M Buy
127,215
+64,251
+102% +$1.34M ﹤0.01% 2023
2014
Q1 		$1.53M Sell
62,964
-7,753
-11% -$196K ﹤0.01% 2643
2013
Q4 		$1.77M Buy
70,717
+30,913
+78% +$729K ﹤0.01% 2638
2013
Q3 		$1.09M Sell
39,804
-57,838
-59% -$1.21M ﹤0.01% 2961
2013
Q2 		$1.77M Buy
+97,642
New +$1.34M ﹤0.01% 2243

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

D.E. Shaw & Co's ACAD Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Acadia Pharmaceuticals (ACAD) stake by 29% in Q1 2026, selling an estimated $7.1M and leaving 729,836 shares worth $16.2M. The position accounts for 0.01% of the portfolio, ranked #1281.

D.E. Shaw & Co first reported a position in ACAD in Q2 2013 and has held it in 48 quarters since. The position peaked at $126M in Q2 2023. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • D.E. Shaw & Co held 729,836 shares of Acadia Pharmaceuticals worth $16.2M as of Q1 2026.
  • D.E. Shaw & Co sold 296,949 Acadia Pharmaceuticals shares in Q1 2026, an estimated $7.1M.
  • Acadia Pharmaceuticals made up 0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #1281 holding.
  • D.E. Shaw & Co first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 48 quarters since.
  • D.E. Shaw & Co's Acadia Pharmaceuticals position peaked at $126M in Q2 2023.
  • 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.